Self-amplyfing RNA technologies create unprecedented opportunity to increase mRNA therapeutics safety and efficacy.
Book a demo
Viriome is a young biotech company developing a breakthrough therapeutic mRNA delivery platform based on modified bacteriophages. This solution redefines the standards of gene therapy and next-generation vaccines.
Our technology addresses the limitations of current mRNA delivery methods—such as lipid nanoparticles (LNPs), and traditional viral vectors—which are often associated with risks like immune reactions, high production costs, and low targeting efficiency.
Our technology addresses the limitations of current mRNA delivery methods - such as lipid nanoparticles (LNPs), and traditional viral vectors - which are often associated with risks like immune reactions, high production costs, and low targeting efficancy.
Bacteriophages are viruses that naturally infect bacteria and are safe for humans. They offer unique capabilities for precise, safe, and effective mRNA transport. Thanks to the ease of modifying the capsid and the ability to engineer surface properties, our system enables targeted mRNA delivery directly into the cell cytoplasm, without requiring genetic modification of patient cells.
Viriome’s phage vectors feature mechanisms that allow them to escape endosomes and directly export replicated mRNA into the cytoplasm. This innovation significantly boosts transfection efficiency and eliminates the risk of insertional mutagenesis, a concern with some viral vector systems.
Amplification of delivered mRNA enhances therapy safety and effectiveness by lowering the required dose and increasing therapeutic mRNA expression.
Imagine a future where life-saving therapies are not only more effective but also safer, cheaper, and accessible to people around the world. This is the future Viriome is building.
Today’s mRNA therapies—like vaccines and cancer treatments—rely on complex delivery systems that can trigger immune reactions, are expensive to produce, and often struggle to reach the right cells. We set out to change that.
Unlike traditional methods, our bacteriophage-based system:
Amplifies the delivered mRNA, making treatments more powerful and longer-lasting with smaller doses,
Stays stable without the need for deep freezing, making distribution around the world much easier,
Targets specific cells, opening the door to highly personalized cancer therapies,
And dramatically lowers production costs, making innovative treatments available to many more people.
Watch our 2-minute explainer video to understand better how our project works.
Viriome: Safer. Smarter. More accessible mRNA therapies for everyone.
Viriome’s platform introduces a range of unique technological improvements that distinguish it from existing mRNA delivery methods, thereby enhancing the treatment’s efficacy, safety, and cost-effectiveness.
Furthermore, the improved stability of mRNA carriers reduces the environmental burden associated with current therapeutic mRNA technologies by lowering the carbon footprint and minimizing the production of toxic byproducts. Through this innovative approach, modified phages establish a new standard for gene therapy and mRNA vaccines.
Therapeutic mRNA is exported directly from the phage capsid into the cell cytoplasm, eliminating the need for nuclear import mechanisms. This makes transfection more efficient, independent of the host genome integration, and removes the risk of insertional mutagenesis, a concern with retro- and lentiviral vectors.
Capsid modifications, and the integration of signal sequences allow for designing vectors that recognize not only specific cell types but also compartments, opening new paths for personalized cancer therapies.
Using a prokaryotic expression system makes our platform much cheaper to produce compared to traditional mRNA delivery methods. The system is easily scalable in laboratory and industrial settings, enabling rapid, broad deployment.
Phage vectors amplify delivered mRNA, extending the duration of therapeutic protein expression and significantly lowering the required therapeutic dose. Dose reduction is a key step towards eliminating the adverse effects of the treatment.
High stability and environmental resistance simplify storage and transportation, removing the need for cold chain logistics used for current mRNA therapies.
Lower production costs, simplified logistics, and high product stability allow deployment in highly developed healthcare systems and developing countries. This provides a real opportunity to expand access to innovative mRNA therapies worldwide.
It’s also important to note that market analyses unanimously project that emerging markets—especially in Asia and the South Pacific—will play a crucial role in the global growth of the mRNA therapeutics market. Penetrating these emerging markets will be key between 2025 and 2035. Decentralized mRNA drug production, enabled by using prokaryotic expression systems, is designed to facilitate this expansion.
The therapeutic mRNA market is in a rapid growth phase and is considered one of the most promising segments in biotechnology. The global mRNA market is projected to be worth USD 19.6 billion in 2025, with an expected increase to USD 85.9 billion by 2035. This represents a compound annual growth rate (CAGR) of 14.6%.
These promising forecasts are driven by rising demand for modern, precise, and effective treatments—especially in oncology, rare diseases, and vaccine development.
Viriome is perfectly positioned within this trend. Our innovative mRNA delivery platform, based on engineered bacteriophages, addresses the core technological and economic challenges of the field. By reducing costs, simplifying production, and expanding access to therapies, Viriome aims to reshape the current market landscape.
We cooperate closely with some of the best polish genetic engineering laboratories to extend our access to the exclusive infrastructure and know-how.
We’re currently in the process of establishing strategic partnerships building the best possible ecosystem for technological validation and commercialization of our solutions.
short info
short info
PhD – Scientific Advisor
An experienced researcher with many years of hands-on work in molecular biology and cancer research. He specializes in advanced cell culture techniques and gene expression analysis. Co-author of scientific publications and projects in gene therapy using retroviral vectors.
At Viriome, he is responsible for:
scientific validation of solutions, experiment consulting, and interpretation of research results.
Co-founder
A young scientist passionate about molecular virology and medical biotechnology. Creator of Viriome's core technology. A medical student and two-time recipient of the Rector's Scientific Scholarship for top students at the medical faculty. While still in school, he secured three research grants as a project lead. His experience includes advanced lab work with 2D and 3D cell cultures, constructing recombinant genetic constructs, and conducting molecular analyses of nucleic acid expression.
At Viriome, he is responsible for:
identifying areas with no effective therapeutic options and designing innovative medical solutions to address unmet clinical needs.
Co-founder
An experienced manager and business strategist, responsible for overall project management at Viriome. He focuses on early-stage tech company development, blending practical knowledge in business development, market analysis, and operational management. He brings strong experience in negotiations and building relationships with investors and strategic partners. As a leader, he’s skilled at integrating cross-functional teams – from scientists and engineers to business experts – to ensure effective execution of goals.Thanks to his unique mix of expertise in law, management, and innovation, he successfully guides Viriome through all key development stages: from scientific concept, through partnership building and legal oversight, to preparing for international market entry.
At Viriome, he is responsible for:
team coordination, business strategy development, partner acquisition, fundraising, and supervision of both operational and legal processes.
Clinical Advisor
A clinical oncology specialist with extensive experience treating cancer patients. She’s an expert in modern treatment methods, including targeted therapies and immunotherapy. Passionate about supporting the development of biotech innovation in oncology.
At Viriome:
she focuses on adapting solutions to real clinical needs, scientific validation, experiment consulting, and interpretation of research results.
